Gilead Sciences (GILD) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY25 Guidance

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $2.01, $0.05 better than the analyst estimate of $1.96. Revenue for the quarter came in at $7.1 billion versus the consensus estimate of $6.97 billion.

GUIDANCE:

Gilead Sciences sees FY2025 EPS of $7.95-$8.25, versus the consensus of $8.00. Gilead Sciences sees FY2025 revenue of $28.3-28.7 billion, versus the consensus of $28.7 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Ennis (EBF) Misses Q2 EPS by 2c
• MVB Bank partners with Kobalt Labs to automate compliance workflows